SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A fair growth of 5.27% in the revenue at Rs. 9533.80 millions was reported in the September 2023 quarter as compared to Rs. 9056.10 millions during year-ago period.A slim rise of 11.36% was recorded in the Net profit for the quarter ended September 2023 to Rs. 2155.40  millions  From Rs. 1935.60 millions.Operating profit for the quarter ended September 2023 rose to 3150.50 millions as compared to 2790.80 millions of corresponding quarter ended September 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 9533.80 9056.10 5.27 16914.00 16350.70 3.45 32163.40 32175.10 -0.04
Other Income 284.70 221.60 28.47 652.70 499.50 30.67 1015.20 762.20 33.19
PBIDT 3150.50 2790.80 12.89 4931.00 4548.00 8.42 9009.30 8320.50 8.28
Interest 4.30 3.90 10.26 7.10 10.70 -33.64 18.10 19.90 -9.05
PBDT 3146.20 2786.90 12.89 5096.90 4537.30 12.33 8981.50 8416.40 6.71
Depreciation 181.10 163.60 10.70 344.70 321.80 7.12 657.70 681.90 -3.55
PBT 2965.10 2623.30 13.03 4752.20 4215.50 12.73 8323.80 7734.50 7.62
TAX 809.70 687.70 17.74 1291.00 1123.60 14.90 2276.80 3968.70 -42.63
Deferred Tax -96.30 -46.30 107.99 -141.30 -81.00 74.44 -183.70 -105.00 74.95
PAT 2155.40 1935.60 11.36 3461.20 3091.90 11.94 6047.00 3765.80 60.58
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 33.05 30.82 7.23 29.15 27.82 4.81 28.01 25.86 8.32

Glaxosmithkline Phar Share Price

2437.80 -14.00 (-0.57%)
20-Apr-2026 15:06 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.95
Dr. Reddys Lab 1233.20
Cipla 1231.45
Zydus Lifesciences 937.70
Lupin 2329.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×